Opens in a new tab

CTE Blood Test: What the New JAMA Studies Show About Detecting CTE in Life

Table of Content

CTE blood test: a lab scientist holds a plasma tube beside a brain with tau tangles and a football helmet

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

On November 19, 2026, JAMA published a Boston University study suggesting that a simple blood draw may one day help detect chronic traumatic encephalopathy (CTE) in living people. Until now, CTE, the brain disease linked to years of repeated hits to the head, could only be confirmed by examining the brain after death.

The study measured a fragment of the tau protein in the blood, called eMTBR-tau, in former American football players who later donated their brains. A second JAMA paper from Washington University in St. Louis, published on November 13, found the same signal with a different lab method. Here is what the CTE blood test research shows, what it cannot do yet, and which blood tests are actually used today after a head injury.

What the Boston University team studied

The researchers worked with 21 men who had played American football (12 professionally, 7 in college and 2 in high school). Each one gave a blood sample while alive as part of research at the BU CTE Center, then died and donated his brain. That design is rare and valuable: it lets scientists compare a blood result with the actual damage seen under the microscope.

  • 18 of the 21 donors had CTE at autopsy: 16 at a high stage (stage III or IV) and 2 at a low stage.
  • 5 of the donors with CTE also had Alzheimer's disease changes in the brain.
  • Blood samples were tested at the Banner Sun Health Research Institute in Arizona with a new antibody-based test (immunoassay) for eMTBR-tau, together with p-tau217, the best-known Alzheimer's blood marker.

The results: a signal for advanced CTE

Blood eMTBR-tau was clearly higher in people with high-stage CTE than in people with low-stage CTE or no CTE. The more tau tangles the brain contained across 11 regions, the higher the blood level. The difference held even after the 5 donors with Alzheimer's changes were set aside, and the highest levels of all were seen in people who had both CTE and Alzheimer's disease.

In contrast, p-tau217 was not linked to CTE itself: it rose mainly in donors who also had Alzheimer's changes. In other words, the two markers seem to tell different stories, which could one day help doctors tell the two diseases apart.

The Washington University study (Horie and colleagues) used mass spectrometry, a different lab technique, on 229 people. In 11 people with autopsy-confirmed CTE, plasma eMTBR-tau243 separated stage III and IV CTE from healthy controls very well, but it did not reliably detect stage I CTE. Levels in CTE were also much lower than in Alzheimer's disease.

Why this matters for people with repeated head impacts

CTE has been found in former contact sport athletes, including football, ice hockey, soccer, rugby and wrestling, and in some military veterans. According to the CDC, the only way to confirm CTE today is to examine the brain after death, and scientists are still not certain which symptoms are directly caused by it. Families often report problems with memory, mood, behavior and suicidal thoughts, but these symptoms have many possible causes.

A reliable blood test would change three things: it could help doctors identify CTE during life, follow people at risk over time, and select participants for future treatment trials that target tau.

The limits: what this blood test cannot do yet

  • It is not FDA-approved for CTE and should not be used to make a CTE diagnosis today, as the BU researchers themselves stress.
  • The samples were small: 21 donors in one study, 11 people with CTE in the other.
  • Early-stage CTE was poorly detected, and the BU study had no age-matched controls.
  • eMTBR-tau also rises in Alzheimer's disease and in some inherited forms of frontotemporal dementia, so it cannot be a standalone CTE test.
  • The marker was developed at Washington University and licensed to C2N Diagnostics, but no commercial version is validated for CTE.

Which tests can monitor or screen for this?

No routine blood test can diagnose CTE. After a head injury or in someone with memory or mood changes, these are the tests doctors actually use:

SituationTestWhat it tells you
Recent head injury (within 12 to 24 hours)GFAP and UCH-L1 blood testFDA-cleared in adults to help decide whether a head CT scan is needed; a negative result makes bleeding in the brain very unlikely
Memory or thinking problemsVitamin B12, TSH, glucose or HbA1c, sodium, complete blood countLooks for treatable causes such as B12 deficiency, thyroid disease, diabetes or anemia
Suspected Alzheimer's diseaseAlzheimer's blood tests (p-tau217), spinal fluid tests, amyloid PETUsed in specialist care to detect Alzheimer's changes, which often coexist with CTE
CTEeMTBR-tau blood testResearch only; not available for diagnosis

For background, see our articles on the tau blood test that estimates Alzheimer's stage, the bedside blood tests used for stroke, the vitamin B12 blood test and TSH testing.

Recent advances in research

  • Studies of young brain donors who played contact sports have shown that CTE changes can already be present in people in their twenties, mostly at early stages, and that many of these young athletes had symptoms whether or not CTE was found.
  • Research on hundreds of brain donors exposed to repeated head impacts shows that CTE rarely comes alone: Alzheimer's disease, TDP-43 changes and blood vessel damage often add up and together explain memory problems.
  • A community autopsy study found CTE mostly in people with long exposure to repeated head impacts, and only rarely after a single brain injury.
  • Blood tests for acute brain injury (GFAP and UCH-L1) have moved from research to routine emergency use in the US and Europe, including faster lab platforms and studies in children.
  • The new JAMA studies are the first to tie a blood marker to tau tangles that are typical of CTE, confirmed at autopsy.

When to see a doctor

  • Call 911 after a head injury with loss of consciousness, a worsening headache, repeated vomiting, confusion, seizures, weakness or slurred speech.
  • See a doctor before returning to sport after any suspected concussion.
  • Make an appointment if you have played contact sports or served in the military and notice changes in memory, mood, behavior or impulse control.
  • If you have thoughts of suicide, call or text 988 (Suicide and Crisis Lifeline) right away.

Glossary

  • Chronic traumatic encephalopathy (CTE): a brain disease linked to years of repeated head impacts, defined by tau buildup around small blood vessels at the bottom of brain folds.
  • Tau protein: a protein that supports the internal skeleton of nerve cells; in CTE and Alzheimer's disease it clumps into tangles.
  • eMTBR-tau: a fragment of tau found in blood that reflects tau tangles in the brain.
  • p-tau217: a form of tau that rises early in Alzheimer's disease and is used in Alzheimer's blood tests.
  • CTE stage: a scale from I to IV that describes how far tau lesions have spread in the brain.
  • GFAP and UCH-L1: proteins released by brain cells after an acute injury, measured in emergency blood tests.
  • Repeated head impacts: hits to the head, with or without concussion symptoms, repeated over months or years.

FAQ

Can I get a CTE blood test today?

No. The eMTBR-tau test is a research tool. It is not FDA-approved for CTE and no lab offers it to diagnose the disease.

How is CTE diagnosed right now?

CTE can only be confirmed by examining the brain after death. During life, doctors can only assess symptoms and a history of head impacts, and rule out other causes.

Does one concussion cause CTE?

According to the CDC, there is no strong evidence that one or a few concussions lead to CTE. It is mainly linked to long-term exposure to repeated head impacts.

Is there a blood test for concussion?

Yes. A GFAP and UCH-L1 blood test is FDA-cleared for adults to help decide whether a CT scan is needed after a recent head injury. It does not diagnose concussion itself or CTE.

Is this the same test as the Alzheimer's blood test?

No. Alzheimer's blood tests mostly measure p-tau217 or amyloid ratios. eMTBR-tau is a newer marker that rises in Alzheimer's disease and in advanced CTE.

Sources

Other articles

Understand your own blood test results with AI DiagMe

Have a recent blood test with values outside the normal range, such as vitamin B12, TSH or glucose? Upload your lab report to AI DiagMe to get a clear explanation of each result in minutes and prepare questions for your doctor.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practicing hospital physicians in specialties such as hematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr. Claude Tchonko is a hematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specializes in the management of hematologic malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimization of care pathways in onco-hematology.

    Author of a reference work, “Lymphoid Hematologic Malignancies in Mali”, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Hematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Hematology and an inter-university diploma (DIU) in Onco-Hematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming Soon